1 / 17

HIV-1 drug resistance in a rural HIV clinic in Coastal Kenya.

HIV-1 drug resistance in a rural HIV clinic in Coastal Kenya. Amin Hassan KEMRI/ Wellcome Trust Research Programme, Kilifi , Kenya 22 nd November 2013. Layout. Background Objective Methods Results Summary Acknowledgement. HIV in Kenya. Generalized HIV epidemic

aquila
Download Presentation

HIV-1 drug resistance in a rural HIV clinic in Coastal Kenya.

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. HIV-1 drug resistance in a rural HIV clinic in Coastal Kenya. Amin Hassan KEMRI/Wellcome Trust Research Programme, Kilifi, Kenya 22nd November 2013

  2. Layout • Background • Objective • Methods • Results • Summary • Acknowledgement HIV-1 drug resistance in Kenya

  3. HIV in Kenya • Generalized HIV epidemic • Prevalence, 5.6% (Kenya AIDS Indicator Survey 2012) • People living with HIV, 1.6 million in 2011 (AIDS Epidemic Update 2011) • Scale up of antiretroviral therapy • 10000 (2003) to ~500000 (2012); 72% coverage (UNAIDS 2012) • Reduction in HIV-related morbidity and mortality • Emergence and transmission of HIVDR HIV-1 drug resistance in Kenya

  4. HIVDR in Kenya • Transmitted HIVDR: • Initially, low levels of <5% (Hamers R. et al, 2011; Price M. et al, 2011) • Recently, high prevalence: 9/68 (13.2%) (Sigaloff K. et al, 2012) • Acquired HIVDR: • Overall prevalence: 14/132 (10.6%) (Steegen K et al, 2009) • Predominant mutations: M184V, K103N • Paucity of HIVDR data from rural Kenya HIV-1 drug resistance in Kenya

  5. Objective • To describe HIV-1 transmitted and acquired drug resistance in a rural HIV clinic in Coastal Kenya. HIV-1 drug resistance in Kenya

  6. Study site HIV-1 drug resistance in Kenya

  7. Study setting • Standardised public health approach • ART eligibility: CD4 count <350 and/or WHO stage III/IV • First line: 2 NRTIs + 1 NNRTI • Second line: 2 NRTIs + boosted PI • Routine monitoring: Clinical and Immunological • Targeted monitoring: Virological and Drug resistance testing HIV-1 drug resistance in Kenya

  8. Study design • Cross sectional surveys, 2008 – 2011 • Eligibility: • Adults (>15 years) • Transmitted HIVDR: ART naïve, enrolling for HIV care • Acquired HIVDR: on 1st line ART, >6 months • Use of remnant samples from routine CD4 counts HIV-1 drug resistance in Kenya

  9. Laboratory methods • Plasma viral load quantification: • In house assay, viremia >400 cpm • HIVDR genotyping: • In-house assay (Cane P. , 2011) • Amplified and sequenced pol region • Sequences submitted to Stanford HIVDR database • TDR: WHO list for surveillance of TDR HIV-1 drug resistance in Kenya

  10. Transmitted HIVDR (N=182) • Females: 138 (76%) • Mean age: 35 years • Transmitted HIVDR: 2/182, 1.1% (95% CI, 0.1 – 3.9) HIV-1 drug resistance in Kenya

  11. Viremia and Acquired HIVDR (N=232) • Median duration on ART: 14 months (IQR: 10 - 18) • HIV-1 Viremia: 25% (95% CI: 19 - 31) • Acquired HIVDR: 13% (95% CI: 9 - 18 ) HIV-1 drug resistance in Kenya

  12. Acquired HIVDR mutations (N=29) Dual-class resistance, n= 25 (86%) HIV-1 drug resistance in Kenya

  13. Correlates of Viremia, Acquired DR (N=232) *Adjusted for gender, marital status, education status, baseline regimen, drug substitution and duration on ART. HIV-1 drug resistance in Kenya

  14. Viremia and Acquired HIVDR by age (N=232) HIV-1 drug resistance in Kenya

  15. Limitations • Generalizability • Transmitted HIVDR: • Inability to determine acute HIV infections • Reported ART exposure • Acquired HIVDR: • Cross sectional design, one-off plasma viral load HIV-1 drug resistance in Kenya

  16. Summary • Conclusions • Low levels of transmitted HIVDR; geographic variations • Viremia and Acquired HIVDR comparable to other settings • Recommendations • Continued surveillance for transmitted and acquired HIVDR • Prioritize and strengthen adherence support • Youth friendly ART support and initiatives HIV-1 drug resistance in Kenya

  17. Acknowledgement • KEMRI/Wellcome Trust Research Programme • James Berkley • Eduard Sanders • PASER / University of Amsterdam • Tobias F. Rinke de Wit • Health Protection Agency, London • Pat Cane • Antiviral unit • Patients and staff at the HIV clinic, Kilifi District Hospital HIV-1 drug resistance in Kenya

More Related